SBSam de Blank

Sam de Blank

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sam de Blank has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    De novo H3.3K27M-altered diffuse midline glioma in human brainstem organoids to dissect GD2 CAR T cell function

    by Nils Bessler, Amber K. L. Wezenaar, Hendrikus C. R. Ariese, Celina Honhoff, Noëlle Dommann, Ellen J. Wehrens, Cristian Ruiz Moreno, Thijs J. M. van Den Broek, Raphaël V. U. Collot, Daan J. Kloosterman, et al.

    Diffuse midline glioma (DMG) is a highly aggressive and untreatable pediatric cancer primarily arising in the pontine brainstem region, necessitating the development of representative models for treatment advance. Here we developed an FGF4-driven human brainstem organoid model, which we used to genetically engineer H3.3K27M-altered DMG. We demonstrated that brainstem pontine glial specification is critical for DMG tumorigenesis, yielding infiltrative tumors that recapitulate patient-representative intratumoral heterogeneity. Prolonged GD2 chimeric antigen receptor (CAR) T cell treatment mirrored clinical outcomes and revealed extensive transcriptional heterogeneity, from which both potent effector and dysfunctional CAR T cell populations could be identified. Furthermore, incorporation of myeloid cells generated DMG-specific microglia that reduced treatment efficacy and revealed CAR T cell functional states most vulnerable to microglia-mediated immunosuppression. Thus, we present a representative DMG model offering a months-long experimental window in vitro, which we leveraged to delineate CAR T cell functionality and microglial impact, aiding therapy development for this devastating disease.


  • Open Access

    Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function

    by Marta Barisa, Henrike P Muller, Elisa Zappa, Rivani Shah, Juliane L Buhl, Benjamin Draper, Courtney Himsworth, Chantelle Bowers, Sophie Munnings-Tomes, Marilena Nicolaidou, et al.

    Chimeric Antigen receptor T cell (CAR-T) treatments for solid cancers have been compromised by limited expansion and survival in the tumor microenvironment following interaction with antigen-expressing target cells. Using B7H3 as a model antigen with broad clinical applicability, we evaluate the relationship between the antibody/antigen affinity of three clinical candidate binders and the three following characteristics: cellular avidity, duration of sustained cytotoxicity in tumoroid re-stimulation assays, and in vivo anti-tumoral responses. Next, BEHAV3D video microscopy is used to assess CAR-T cell interaction with tumor cells at single cell resolution. These data are consistent with a threshold avidity of CAR-T / tumor cell interaction and target cell B7H3 expression level, where enhanced functionality is characterized by longer cumulative CD8+ CAR-T / tumor target interaction times, CAR-T cell expansion and sustained tumor control. Lower checkpoint receptor expression does not correlate with enhanced anti-tumor function. These results provide further insights into design of anti-B7H3 CAR-T cells for antigen-dim cell targeting, and avoidance of antigen-dim tumor relapse.


  • Mapping T cell dynamics to molecular profiles through behavior-guided transcriptomics

    by A. K. L. Wezenaar, U. Pandey, F. Keramati, M. Hernandez-Roca, P. Brazda, M. Barrera Román, A. Cleven, F. Karaiskaki, T. Aarts-Riemens, S. de Blank, et al.

    The rise of cellular immunotherapy for cancer treatment has led to the utilization of immune oncology cocultures to simulate T cell interactions with cancer cells for assessing their antitumor response. Previously, we developed BEHAV3D, a three-dimensional live imaging platform of patient-derived tumor organoid (PDO) and engineered T cell cocultures, that analyzes T cells’ dynamics to gain crucial insights into their behavior during tumor targeting. However, live imaging alone cannot determine the molecular drivers behind these behaviors. Conversely, single-cell RNA sequencing (scRNA-seq) allows researchers to analyze the transcriptional profiles of individual cells but lacks spatio-temporal resolution. Here we present an extension to the BEHAV3D protocol, called Behavior-Guided Transcriptomics (BGT), for integration of T cell live imaging data with single-cell transcriptomics, enabling analysis of gene programs linked to dynamic T cell behaviors. BGT uses live imaging data processed by BEHAV3D to guide the experimental setup for cell separation based on their PDO engagement levels subsequently followed by fluorescence-activated cell sorting and scRNA-seq. It then integrates in silico simulations of these experiments to computationally infer T cell behavior on scRNA-seq data, uncovering new biomarkers for both highly functional and ineffective T cells, that could be exploited to enhance therapeutic efficacy. The protocol, designed for users with fundamental cell culture, imaging and programming skills, is readily adaptable to diverse coculture settings and takes one month to perform.


  • Open Access

    A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery

    by Bernadette Jeremiasse, Ravian L van Ineveld, Veerle Bok, Michiel Kleinnijenhuis, Sam de Blank, Maria Alieva, Hannah R Johnson, Esmée J van Vliet, Amber L Zeeman, Lianne M Wellens, et al.

    Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.


  • BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response

    by Maria Alieva, Mario Barrera Román, Sam de Blank, Diana Petcu, Amber L. Zeeman, Noël M. M. Dautzenberg, Annelisa M. Cornel, Cesca van de Ven, Rob Pieters, Monique L. Den Boer, et al.

    Modeling immuno-oncology by using patient-derived material and immune cell co-cultures can advance our understanding of immune cell tumor targeting in a patient-specific manner, offering leads to improve cellular immunotherapy. However, fully exploiting these living cultures requires analysis of the dynamic cellular features modeled, for which protocols are currently limited. Here, we describe the application of BEHAV3D, a platform that implements multi-color live 3D imaging and computational tools for: (i) analyzing tumor death dynamics at both single-organoid or cell and population levels, (ii) classifying T cell behavior and (iii) producing data-informed 3D images and videos for visual inspection and further insight into obtained results. Together, this enables a refined assessment of how solid and liquid tumors respond to cellular immunotherapy, critically capturing both inter- and intratumoral heterogeneity in treatment response. In addition, BEHAV3D uncovers T cell behavior involved in tumor targeting, offering insight into their mode of action. Our pipeline thereby has strong implications for comparing, prioritizing and improving immunotherapy products by highlighting the behavioral differences between individual tumor donors, distinct T cell therapy concepts or subpopulations. The protocol describes critical wet lab steps, including co-culture preparations and fast 3D imaging with live cell dyes, a segmentation-based image processing tool to track individual organoids, tumor and immune cells and an analytical pipeline for behavioral profiling. This 1-week protocol, accessible to users with basic cell culture, imaging and programming expertise, can easily be adapted to any type of co-culture to visualize and exploit cell behavior, having far-reaching implications for the immuno-oncology field and beyond.


  • Top Cited Papers
    Open Access

    Uncovering the mode of action of engineered T cells in patient cancer organoids

    by Johanna F. Dekkers, Maria Alieva, Astrid Cleven, Farid Keramati, Amber K. L. Wezenaar, Esmée J. van Vliet, Jens Puschhof, Peter Brazda, Inez Johanna, Angelo D. Meringa, et al.

    Extending the success of cellular immunotherapies against blood cancers to the realm of solid tumors will require improved in vitro models that reveal therapeutic modes of action at the molecular level. Here we describe a system, called BEHAV3D, developed to study the dynamic interactions of immune cells and patient cancer organoids by means of imaging and transcriptomics. We apply BEHAV3D to live-track >150,000 engineered T cells cultured with patient-derived, solid-tumor organoids, identifying a ‘super engager’ behavioral cluster comprising T cells with potent serial killing capacity. Among other T cell concepts we also study cancer metabolome-sensing engineered T cells (TEGs) and detect behavior-specific gene signatures that include a group of 27 genes with no previously described T cell function that are expressed by super engager killer TEGs. We further show that type I interferon can prime resistant organoids for TEG-mediated killing. BEHAV3D is a promising tool for the characterization of behavioral-phenotypic heterogeneity of cellular immunotherapies and may support the optimization of personalized solid-tumor-targeting cell therapies.


  • Revealing the spatio-phenotypic patterning of cells in healthy and tumor tissues with mLSR-3D and STAPL-3D

    by Ravian L. van Ineveld, Michiel Kleinnijenhuis, Maria Alieva, Sam de Blank, Mario Barrera Roman, Esmée J. van Vliet, Clara Martínez Mir, Hannah R. Johnson, Frank L. Bos, Raimond Heukers, et al.

    Despite advances in three-dimensional (3D) imaging, it remains challenging to profile all the cells within a large 3D tissue, including the morphology and organization of the many cell types present. Here, we introduce eight-color, multispectral, large-scale single-cell resolution 3D (mLSR-3D) imaging and image analysis software for the parallelized, deep learning–based segmentation of large numbers of single cells in tissues, called segmentation analysis by parallelization of 3D datasets (STAPL-3D). Applying the method to pediatric Wilms tumor, we extract molecular, spatial and morphological features of millions of cells and reconstruct the tumor’s spatio-phenotypic patterning. In situ population profiling and pseudotime ordering reveals a highly disorganized spatial pattern in Wilms tumor compared to healthy fetal kidney, yet cellular profiles closely resembling human fetal kidney cells could be observed. In addition, we identify previously unreported tumor-specific populations, uniquely characterized by their spatial embedding or morphological attributes. Our results demonstrate the use of combining mLSR-3D and STAPL-3D to generate a comprehensive cellular map of human tumors.


  • Open Access

    Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing

    by Christina Stangl, Sam de Blank, Ivo Renkens, Liset Westera, Tamara Verbeek, Jose Espejo Valle-Inclan, Rocio Chamorro González, Anton G. Henssen, Markus J. van Roosmalen, Ronald W. Stam, et al.

    Fusion genes are hallmarks of various cancer types and important determinants for diagnosis, prognosis and treatment. Fusion gene partner choice and breakpoint-position promiscuity restricts diagnostic detection, even for known and recurrent configurations. Here, we develop FUDGE (FUsion Detection from Gene Enrichment) to accurately and impartially identify fusions. FUDGE couples target-selected and strand-specific CRISPR-Cas9 activity for fusion gene driver enrichment — without prior knowledge of fusion partner or breakpoint-location — to long read nanopore sequencing with the bioinformatics pipeline NanoFG. FUDGE has flexible target-loci choices and enables multiplexed enrichment for simultaneous analysis of several genes in multiple samples in one sequencing run. We observe on-average 665 fold breakpoint-site enrichment and identify nucleotide resolution fusion breakpoints within 2 days. The assay identifies cancer cell line and tumor sample fusions irrespective of partner gene or breakpoint-position. FUDGE is a rapid and versatile fusion detection assay for diagnostic pan-cancer fusion detection.